Recent Updates
Recently added Catalysts

Pneumococcal 13-valent Conjugate Vaccine

Phase 3

Healthy Volunteers (Meningococcal Infection) | Monoclonal antibody | Other |Sanofi|Last Updated: Dec 14, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment2,797
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT03673462Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and ToddlersPHASE3 COMPLETED 2,797Sep 17, 2018Mar 16, 2023Dec 14, 202369 United States, Puerto Rico
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
Within 30 minutes post-any vaccination

An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not have any causal relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Immediate adverse events are unsolicited systemic adverse events occurring in the 30 minutes after injection. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Solicited Injection Site Reactions
Within 7 days post any vaccination

A solicited reaction was an "expected" adverse reaction (AR) (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited injection site reactions included Injection site tenderness, Injection site erythema, and Injection site swelling and were planned to be collected and reported for each vaccine separately; and not planned to be collected for Rotavirus vaccine as the vaccine was administered orally, and no injection site reactions were expected to occur. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Solicited Systemic Reactions
Within 7 days post-any vaccination

A solicited reaction was an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB and considered as related to the product administered. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss, and irritability. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Unsolicited Adverse Events
Within 30 days post any vaccination

An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product, and which does not necessarily have a causal relationship with this treatment. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious adverse events (SAEs) and non-serious unsolicited AEs. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Serious Adverse Events (SAEs) and Adverse Event of Special Interest (AESIs)
From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)

A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An AESI (serious or non-serious) was defined as one of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate. Reported AEs for each arm were presented as pre-specified in protocol.

Number of Participants With Medically Attended Adverse Event (MAAEs)
From day of first vaccination (i.e., at the age of 2 months) up to 6 months after last vaccination (i.e., up to the age of 18 months)

A MAAE was defined as a new onset of a condition that prompts the participant or participant's parent/guardian to seek unplanned medical advice at a health care provider's office or Emergency Department. Reported AEs for each arm were presented as pre-specified in protocol.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Group 1: MenACYW Conjugate VaccineEXPERIMENTALHealthy infants aged greater than equal to (\>=) 42 to less than equal to (\<=) 89 days (at the time of enrollment) received MenACYW Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (pneumococcal 13-valent conjugate vaccine; PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
Group 2: MENVEO®ACTIVE_COMPARATORHealthy infants aged \>= 42 to \<= 89 days (at the time of enrollment) received MENVEO® Conjugate Vaccine at the age of Months 2, 4, 6, and 12 along with Pentacel® (DTaP-IPV/Hib vaccine) at 2, 4, and 6 months of age; PREVNAR 13® (PCV13) at 2, 4, 6, and 12 months of age; RotaTeq® (rotavirus vaccine) at 2, 4, and 6 months of age; ENGERIX-B® (hepatitis B vaccine) at 2 and 6 months of age; and M-M-R® II (measles, mumps, and rubella vaccine) and VARIVAX® (varicella vaccine) at 12 months of age.
Interventions
NameTypeDescription
Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid Conjugate vaccine (MenACYW Conjugate vaccine)BIOLOGICALPharmaceutical form: Liquid solution. Route of administration: Intramuscular
Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MENVEO®)BIOLOGICALPharmaceutical form: Lyophilized powder combined with liquid components Route of administration: Intramuscular
Diphtheria, Tetanus, Acellular Pertussis, Poliovirus and Haemophilus b VaccineBIOLOGICALPharmaceutical form: Liquid DTaP-IPV to reconstitute lyophilized ActHIB Route of administration: Intramuscular
Pneumococcal 13-valent Conjugate VaccineBIOLOGICALPharmaceutical form: Suspension for injection Route of administration: Intramuscular
Rotavirus VaccineBIOLOGICALPharmaceutical form: Oral solution Route of administration: Oral
Hepatitis B VaccineBIOLOGICALPharmaceutical form: Suspension for injection Route of administration: Intramuscular
Measles, Mumps, and Rubella Virus VaccineBIOLOGICALPharmaceutical form: Lyophilized live virus vaccine Route of administration: Subcutaneous
Varicella Virus VaccineBIOLOGICALPharmaceutical form: Suspension for injection Route of administration: Subcutaneous
Unlock Study Design Details
Eligibility Criteria
Age Range42 Days — 89 Days
SexALL
Healthy VolunteersYes
Study Sites69

Inclusion criteria: * Aged \>= 42 to \<= 89 days on the day of the first study visit. * Healthy infants as determined by medical history, physical examination, and judgment of the investigator. * Informed consent form was signed and dated by the parent(s) or guardian (and by an independent witness ...

Countries:United StatesPuerto Rico
Unlock Eligibility Criteria